Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fosun Completes Half of $30 Million Investment in Chindex

publication date: Aug 30, 2010
Chindex International said Fosun Pharmaceutical has purchased 933,022 of its shares at $15 per share. The investment is part of a previously announced transaction that will establish a medical device JV between the two companies. Chindex is spinning off its medical device manufacturing and distribution business into the JV, which will be owned 51% by Fosun.  More details....

Stock Symbols: (NSDQ: CHDX)  (SHEX: 600196)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital